MedTrace Logo

Patient-Derived Xenografts to Reduce Cancer Health Disparities

NCT04410302 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-08-20

No results posted yet for this study

Summary

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

Conditions

  • Bladder Carcinoma
  • Gastric Carcinoma
  • Liver and Intrahepatic Bile Duct Carcinoma
  • Lung Carcinoma
  • Malignant Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of tumor tissue, blood, saliva, and urine samples

Sponsors & Collaborators

Principal Investigators

  • Luis G Carvajal-Carmona · University of California, Davis

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2026-12-31
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04410302 on ClinicalTrials.gov